{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:26:35Z","timestamp":1790270795635,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116685","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:43:44Z","timestamp":1774658624000},"page":"116685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)"],"prefix":"10.1016","volume":"239","author":[{"given":"Nicoletta","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-0448","authenticated-orcid":false,"given":"Gabriella","family":"Parma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Pio","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germana","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3139-0972","authenticated-orcid":false,"given":"Andrea Alberto","family":"Lissoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roldano","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-5066","authenticated-orcid":false,"given":"Luciano","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5427-052X","authenticated-orcid":false,"given":"Massimo","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-3699","authenticated-orcid":false,"given":"Annamaria","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mantiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7380-577X","authenticated-orcid":false,"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionyssios","family":"Katsaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tomao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-7306","authenticated-orcid":false,"given":"Francesca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Lapresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ficarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Canova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Derio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-7986","authenticated-orcid":false,"given":"Fabio","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zizioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalissa","family":"Katrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-4055","authenticated-orcid":false,"given":"Davide","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-4137","authenticated-orcid":false,"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-3827","authenticated-orcid":false,"given":"Elena","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2026.116685_bib1","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116685_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ejca.2026.116685_bib3","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2026.116685_bib4","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2026.116685_bib5","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2026.116685_bib6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116685_bib7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116685_bib8","unstructured":"Monk B.J., Parkinson C., Lim M.C., Wilson M.K., Coleman R.L., Lorusso D., et al. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ ENGOT-ov45). J Clin Oncol. 40(34)."},{"issue":"26","key":"10.1016\/j.ejca.2026.116685_bib9","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2026.116685_bib10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116685_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116685_bib12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116685_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116685_bib14","doi-asserted-by":"crossref","unstructured":"Mirza M.R., Gonz\u00e1lez-Mart\u00edn A., Graybill W.S., O\u2019Malley D.M., Gaba L., Stephanie Yap O.W., et al. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Cancer. 2023 Jun 15;129(12):1846-1855. doi:10.1002\/cncr.34706.","DOI":"10.1002\/cncr.34706"},{"issue":"4","key":"10.1016\/j.ejca.2026.116685_bib15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.ejca.2026.116685_bib16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cncr.34705","article-title":"One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit all","volume":"129","author":"Lee","year":"2023","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.ejca.2026.116685_bib17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116685_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clinthera.2024.06.001","article-title":"Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer","volume":"46","author":"Monk","year":"2024","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.ejca.2026.116685_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/ph14080804","article-title":"Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study","volume":"14","author":"Velev","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.ejca.2026.116685_bib20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ygyno.2021.03.015","article-title":"Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2","volume":"161","author":"Konecny","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116685_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae114","article-title":"Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)","volume":"9","author":"Joly","year":"2025","journal-title":"JNCI Cancer Spectr"},{"issue":"5","key":"10.1016\/j.ejca.2026.116685_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105054","article-title":"Exposure\u2013response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO\u2013NiQoLe study","volume":"10","author":"Quesada","year":"2025","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600465X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600465X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:23:37Z","timestamp":1778783017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600465X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["S095980492600465X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116685","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116685"}}